ZVRA

Business Context and Reporting Period

Company: Zevra Therapeutics, Inc. (ZVRA)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Zevra is a commercial-stage biopharmaceutical company focused on rare diseases. Its lead product, MIPLYFFA (arimoclomol), received FDA approval in September 2024 for Niemann-Pick disease type C (NPC) and became commercially available in November 2024. The company also markets OLPRUVA for urea cycle disorders and is advancing celiprolol for Vascular Ehlers-Danlos syndrome (VEDS) and KP1077 for idiopathic hypersomnia.

Key Financial Metrics

Note: 2025 Net Income was significantly driven by a non-recurring gain on the sale of a Priority Review Voucher (PRV).

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased by $82.9 million (351%) to $106.5 million, primarily driven by $77.3 million in MIPLYFFA sales and increased revenue from the global Expanded Access Program (EAP).
• Profitability Shift: The company reported a net income of $83.2 million in 2025 compared to a net loss of $105.5 million in 2024. This turnaround was primarily due to a $148.3 million gain from the sale of the PRV.
• Impairment Charges: The company recorded a $58.7 million impairment charge related to definite-lived intangible assets associated with OLPRUVA in Q2 2025, following a reassessment of commercial prospects.
• Operating Expenses: Research and Development (R&D) expenses decreased by $29.4 million to $12.7 million due to reduced spending on the KP1077 Phase 2 study. Selling, General, and Administrative (SG&A) expenses increased by $22.7 million to $77.6 million to support commercialization efforts.
• Liquidity: Cash and investments increased significantly to $238.9 million, bolstered by the PRV sale proceeds ($148.3 million) and an August 2024 equity offering ($64.5 million).

Guidance, Outlook, Risks, and Unusual Items

• Unusual Items: The $148.3 million gain on the sale of the PRV is a non-recurring item. The $58.7 million impairment charge related to OLPRUVA is also a non-cash, non-recurring charge.
• Outlook: Management expects to continue incurring significant expenses and minimal positive or negative net cash flows from operations in the near future. The company believes its current cash position is sufficient to fund operations for at least the next 12 months.
• Key Risks:
  • Product Dependence: Approximately 82% of 2025 revenue was derived from MIPLYFFA. The company is highly dependent on this single product.
  • Commercialization of OLPRUVA: The company is scaling back sales and marketing for OLPRUVA and evaluating strategic alternatives following the impairment charge.
  • Legal Proceedings: A dispute with Commave regarding the AZSTARYS license agreement is ongoing. Commave filed a complaint in September 2024; a partial summary judgment was granted to Commave in December 2025, with trial scheduled for June 2026.
  • Regulatory: MIPLYFFA's Marketing Authorization Application (MAA) is under review by the European Medicines Agency (EMA).

Investor Verification Checklist

• Sustainability of Profitability: Verify the extent to which future profitability relies on organic product sales versus one-time asset sales (PRV).
• OLPRUVA Strategy: Confirm the specific strategic alternatives being evaluated for OLPRUVA following the $58.7 million impairment.
• Commave Litigation: Monitor the outcome of the trial scheduled for June 2026 regarding the AZSTARYS license agreement and potential financial impact.
• MIPLYFFA Commercialization: Track enrollment numbers (161 as of Dec 31, 2025) and reimbursement rates to assess revenue sustainability given the small patient population.
• Debt Covenants: Review the terms of the $100 million term loan facility, specifically the minimum net product sales and liquidity covenants.